Endocrine Abstracts

Introduction: Once-daily liraglutide and once-weekly dulaglutide, both glucagón-like peptide-1 receptor agonists, improve glycemic control and reduce weight in patients with type 2 diabetes mellitus (T2DM) with a similar efficacy according to head-to-head trial AWARD-6. Nevertheless, there is a lack of evidence in a real-world setting. The focus of our study is to assess changes in glycemic control and weight resulting from switching from liraglutide to dulaglutide in pat...

Introduction: Glucagon-like peptide-1 agonists (GLP1a) and dipeptidyl peptidase-4 inhibitors (DPP4i) are both incretin-based therapies for type 2 diabetes (T2DM) but with distinct efficacy according to glycemic and weight control and side effect profiles. There is scarce information about changes observed after switching from a DPP4i to a GLP1a in patients with T2DM on a complex treatment regimen and routine clinical practice conditions. To assess these changes, we carried out...

Introduction: Graves’ ophthalmopathy (GO) is an autoimmune disorder that constitutes a major clinical and therapeutic challenge. Current treatment options for moderate-to-severe GO include immunotherapy, orbital radiotherapy and decompression surgery. Limited drugs of proven efficacy are available for the treatment of people with GO. Given the role in the pathogenesis of GO of interleukin (IL)-6 expression in adipocytes, fibroblasts and macrophages, the proposed theory i...

Objective: To study the relation between incretin-based therapies, DPP-4 inhibitors and GLP-1 receptor agonists, and tumor stage at the time of diagnosis of pancreatic and biliary tract cancer.Methods: Retrospective study of type 2 diabetic patients with newly diagnosed of pancreatic or biliary tract cancer attended consecutively in a tertiary hospital between the years 2012 and 2015.Results: A total of 37 patients were included. T...

Background: Objective: Non syndromic monogenic obesity is a rare cause of early onset severe obesity in the childhood period. This form may not be distinguishable from other forms of severe obesity without genetic analysis, particularly if patients do not exibit any physical abnormalities or developmental delay. The aim of this study was to screen 41 different obesity-related genes in children with nonsyndromic early onset severe obesity.<p class="abstext"...

Objectives: THRA mutations cause Resistance to Thyroid Hormone α (RTHα), an underdiagnosed disorder with hypothyroid features but near-normal thyroid function tests (TFTs). We developed a pathway, combining molecular analyses, new biomarkers and physiological measurements, to better diagnose and treat this disorder.Methods: Structural and functional analyses of THRA variants, discovered by next generation sequencing in specifi...